- Email: [email protected]
8503357 Improvements relating to growth factors
345
PATENT ABSTRACTS linked polysaccharide sulfate gel, thereby adsorbing F-HA on the gel, and then eluting FHA from the gel. Said method can give a highly purified F-HA which does not contain any other proteins, lipid, saccharides, etc. and further undesirable endotoxin, and hence can be used for producing various reagents, medicines and pertussis vaccine.
4563423 P R O D U C T S DISPLAYING THE ANTIGENICITY OF HEPATITIS B VIRUS E ANTIGENS AND M E T H O D S OF PRODUCING T H O S E ANTIGENS Kenneth Murray, Patricia MacKay, Heidelberg, Federal Republic Of Germany assigned to BiogenN V Polypeptides displaying the antigenicity of hepatitis B virus e antigens, DNA sequences coding for those polypeptides, antibodies to those polypeptides and methods of producing and using those polypeptides, antibodies and DNA sequences. The polypeptides and antibodies of this invention are characterized by their use in compositions and methods for detecting hepatitis B virus infective carriers and in evaluating the course of HBV-related active liver disease.
4563462 SUBSTANCE AX-2, A PROCESS FOR P R O D U C I N G T H E S A M E AND A N A N T I T U M O R COMPOSITION CONTAINING THE SAME Shinzo Ishii, Shigeo Katsumata, Yuko Arai, Tadashi Ashizawa, Makoto Morimoto, Kunikatsu Shirahata, Yutaka Saito, Motomichi Kono. Shizuoka, Japan assigned to Kyowa Hakko Kogyo Kabushiki A substance designated by us as AX-2 and represented by the formula: See Patent for Chemical Structure This substance is produced by culturing a microorganism of the genus Streptomyces and capable of producing AX-2 in a medium to accumulate AX-2 in the cultured broth and isolating AX-2 therefrom. An antitumor composition comprising an effective amount of AX-2 in association with a physiologically acceptable carrier or excipient, which is active against Sarcoma 180.
8503357 I M P R O V E M E N T S RELATING TO GROWTH FACTORS Michael D WATERFIELD, J SCHLESSINGER, Axel ULLRICH, Imperial Cancer Research Fund, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom assigned to ICRF PATENTS LTD: YEDA RESEARCH & DEVELOPMENT CO LTD; GENENTECH INC Neoplastic and other diseases can be diagnosed by assaying a human test sample e.g. body fluid, tissue or cultured tumour explant ceils, for structurally altered or abnormally expressed growth factor receptors or for the nRNA transcripts of genes which encode them. For example, the assay can be for truncated EGF receptor having at least a portion of its mature amino terminus deleted. Antibodies, capable of binding a predetermined amino acid sequence within the EGF receptor, are also useful in diagnosis and therapy as are conjugates of an immunogenic polymer bound to a polypeptide fragment of EGF receptor. DNA and RNA encoding EGF receptor or fragments thereof are also decribed.
8503508 TOXIN CONJUGATES Lawrence I GREENFIELD. Danute E NITECKI, Donald A KAPLAN, David H GELFAND, Michael PIATAK, Glenn HORN assigned to CETUS CORPORATION Toxin conjugates for selective destruction of target cells. Some embodiments employ spacer peptides between the cytotoxic and binding regions of the conjugates to facilitate translocation and intracellular cleavage after binding to the target cell. Components of the conjugate toxins obtained by recombinant techniques are also described. These components include the spacer peptide and portions of diphtheria toxins and of ricin toxins.
8503523 MONOCLONAL ANTI-HUMAN BREAST CANCER ANTIBODIES Arthur E FRANKEL, David B RING, Michael J BJORN assigned to CETUS CORPORATION
PATENT ABSTRACTS linked polysaccharide sulfate gel, thereby adsorbing F-HA on the gel, and then eluting FHA from the gel. Said method can give a highly purified F-HA which does not contain any other proteins, lipid, saccharides, etc. and further undesirable endotoxin, and hence can be used for producing various reagents, medicines and pertussis vaccine.
4563423 P R O D U C T S DISPLAYING THE ANTIGENICITY OF HEPATITIS B VIRUS E ANTIGENS AND M E T H O D S OF PRODUCING T H O S E ANTIGENS Kenneth Murray, Patricia MacKay, Heidelberg, Federal Republic Of Germany assigned to BiogenN V Polypeptides displaying the antigenicity of hepatitis B virus e antigens, DNA sequences coding for those polypeptides, antibodies to those polypeptides and methods of producing and using those polypeptides, antibodies and DNA sequences. The polypeptides and antibodies of this invention are characterized by their use in compositions and methods for detecting hepatitis B virus infective carriers and in evaluating the course of HBV-related active liver disease.
4563462 SUBSTANCE AX-2, A PROCESS FOR P R O D U C I N G T H E S A M E AND A N A N T I T U M O R COMPOSITION CONTAINING THE SAME Shinzo Ishii, Shigeo Katsumata, Yuko Arai, Tadashi Ashizawa, Makoto Morimoto, Kunikatsu Shirahata, Yutaka Saito, Motomichi Kono. Shizuoka, Japan assigned to Kyowa Hakko Kogyo Kabushiki A substance designated by us as AX-2 and represented by the formula: See Patent for Chemical Structure This substance is produced by culturing a microorganism of the genus Streptomyces and capable of producing AX-2 in a medium to accumulate AX-2 in the cultured broth and isolating AX-2 therefrom. An antitumor composition comprising an effective amount of AX-2 in association with a physiologically acceptable carrier or excipient, which is active against Sarcoma 180.
8503357 I M P R O V E M E N T S RELATING TO GROWTH FACTORS Michael D WATERFIELD, J SCHLESSINGER, Axel ULLRICH, Imperial Cancer Research Fund, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom assigned to ICRF PATENTS LTD: YEDA RESEARCH & DEVELOPMENT CO LTD; GENENTECH INC Neoplastic and other diseases can be diagnosed by assaying a human test sample e.g. body fluid, tissue or cultured tumour explant ceils, for structurally altered or abnormally expressed growth factor receptors or for the nRNA transcripts of genes which encode them. For example, the assay can be for truncated EGF receptor having at least a portion of its mature amino terminus deleted. Antibodies, capable of binding a predetermined amino acid sequence within the EGF receptor, are also useful in diagnosis and therapy as are conjugates of an immunogenic polymer bound to a polypeptide fragment of EGF receptor. DNA and RNA encoding EGF receptor or fragments thereof are also decribed.
8503508 TOXIN CONJUGATES Lawrence I GREENFIELD. Danute E NITECKI, Donald A KAPLAN, David H GELFAND, Michael PIATAK, Glenn HORN assigned to CETUS CORPORATION Toxin conjugates for selective destruction of target cells. Some embodiments employ spacer peptides between the cytotoxic and binding regions of the conjugates to facilitate translocation and intracellular cleavage after binding to the target cell. Components of the conjugate toxins obtained by recombinant techniques are also described. These components include the spacer peptide and portions of diphtheria toxins and of ricin toxins.
8503523 MONOCLONAL ANTI-HUMAN BREAST CANCER ANTIBODIES Arthur E FRANKEL, David B RING, Michael J BJORN assigned to CETUS CORPORATION